KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue (2016 - 2026)

Emergent BioSolutions has reported Current Deferred Revenue over the past 15 years, most recently at $17.6 million for Q1 2026.

  • For Q1 2026, Current Deferred Revenue changed N/A year-over-year to $17.6 million; the TTM value through Mar 2026 reached $17.6 million, changed N/A, while the annual FY2025 figure was $5.0 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q1 2026 was $17.6 million at Emergent BioSolutions, up from $5.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $17.6 million in Q1 2026 and troughed at $5.0 million in Q4 2025.
  • A 3-year average of $12.8 million and a median of $15.9 million in 2022 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 85.9% in 2022 and fell as far as 85.9% in 2022.
  • Year by year, Current Deferred Revenue stood at $15.9 million in 2022, then plummeted by 68.55% to $5.0 million in 2025, then soared by 252.0% to $17.6 million in 2026.
  • Business Quant data shows Current Deferred Revenue for EBS at $17.6 million in Q1 2026, $5.0 million in Q4 2025, and $15.9 million in Q1 2022.